NANBIOSIS will participate online this afternoon, September 17, 2026, at 4:00 p.m., in the CIBEROBN Webinars 2026 session “Translational Biomedicine: Disease Mechanisms and Advanced Research Infrastructures.” The webinar is part of the programme organised by the Spanish Biomedical Research Network (CIBEROBN).
The session will focus on “Intestinal proteases in the spotlight: drivers of alcohol-associated liver disease progression”, addressing current research into disease mechanisms and translational biomedicine.
The webinar will also feature an introduction to NANBIOSIS, presented by Gabriel Alfranca, Communication and Internationalization Manager of CIBER-BBN and NANBIOSIS. The presentation will introduce NANBIOSIS as an advanced biomedical research infrastructure supporting research and innovation in areas including nanomedicine, biomaterials and bioengineering.
The event will provide an opportunity to present NANBIOSIS to researchers and other professionals interested in translational biomedical research and advanced research infrastructures.
Date: September 17, 2026
Time: 4:00 p.m.
Format: Online
Programme: CIBEROBN Webinars 2026
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
